## FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

| r subject to | STATEMENT | OF | CHANG | j |
|--------------|-----------|----|-------|---|

SES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL           |           |  |  |  |  |  |  |  |  |
|------------------------|-----------|--|--|--|--|--|--|--|--|
| OMB Number:            | 3235-0287 |  |  |  |  |  |  |  |  |
| Estimated average burd | ourden    |  |  |  |  |  |  |  |  |
| hours per response:    | 0.5       |  |  |  |  |  |  |  |  |

Check this box if no longe Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

|  |  |         |         |            | 1  |  |  |                  |   |                       |            |   |  | 1.  |   |  |           |              | $\overline{}$ |  |
|--|--|---------|---------|------------|--|--|--|------------------|---|-----------------------|------------|---|--|---|---|--|-----------|--------------|---------------|--|
| 1. Name and Address of Reporting Person*                     |  |         |         |            | 2. Issuer Name <b>and</b> Ticker or Trading Symbol       |  |  |                  |   |                       |            |   |  | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) |   |  |           |              |               |  |
| Goodman Vicki L  |  |         |         | IVIU       | Mural Oncology plc [ MURA ]                              |  |  |                  |   |                       |            | `   | Direc  | ,   |   | 10% Ov   | vner      |              |               |  |
|  |  |         |         |            | _  |  |  |                  |   |                       |            |   |  | - [   | ✓ Office below  | er (give title   |           | Other (s     | specify       |  |
| (Last) (First) (Middle)                                      |  |         |         |            |  | 3. Date of Earliest Transaction (Month/Day/Year) |  |                  |   |                       |            |   |  | Chief Medical Officer   |   |  |           |              |               |  |
| C/O MURAL ONCOLOGY PLC                                       |  |         |         | 11/07/2024 |  |  |  |                  |   |                       |            |   |  |   |   |  |           |              |               |  |
| 10 EARLSFORT TERRACE   |  |         |         |            |  |  |  |                  |   |                       |            |   |  |   |   |  |           |              |               |  |
| -  |  |         |         |            | 4. If Amendment, Date of Original Filed (Month/Day/Year) |  |  |                  |   |                       |            |   | 6. Individual or Joint/Group Filing (Check Applicable Line)  |   |   |  |           |              |               |  |
| (Street)   |  |         |         |            |  |  |  |                  |   |                       |            |   |  |   | <u></u>   | filed by One   | a Pano    | ortina Pered | nn.           |  |
| DUBLIN   | 12 L2  | Ε       | 002 T38 | 80         |  |  |  |                  |   |                       |            |   |  | '   | Form filed by One Reporting Person  Form filed by More than One Reporting |  |           |              |               |  |
| -  |  |         |         |            |  |  |  |                  |   |                       |            |   |  |   | Perso   |  | ic triari | TOTIC TROPE  | orting        |  |
| (City)   | (Sta   | ate) (Z | Zip)    |            |  |  |  |                  |   |                       |            |   |  |   |   |  |           |              |               |  |
|  | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned     |         |         |            |  |  |  |                  |   |                       |            |   |  |   |   |  |           |              |               |  |
| 1. Title of Security (Instr. 3)  2. Transact Date (Month/Day |  |         |         |            | Execution Date,  |  | 3. Transaction Code (Instr. 8)  4. Securities Acquired (Disposed Of (D) (Instr. 5) |                  |   | , 4 and Secur<br>Bene |            | ities Fo<br>icially (D)<br>d Following (I)          |  |   | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4)         |  |           |              |               |  |
|  |  |         |         |            |  |  |  | Code             | v   | Amount                | (A) or (D) |   | rice   | Transaction(s)<br>(Instr. 3 and 4)                                      |   |  |           | (111301. 4)  |               |  |
| Ordinary   | Shares   |         |         | 11/07/2    | 2024   |  |  | S <sup>(1)</sup> |   | 5,069                 | Г          | ) 5   | 3.33   | (2) 67  | ,949(3)   |  | D         |              |               |  |
|  | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned        |         |         |            |  |  |  |                  |   |                       |            |   |  |   |   |  |           |              |               |  |
|  |  |         |         |            |  |  |  |                  |   |                       | onvertib   |   |  |   |   |  |           |              |               |  |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)          | erivative Conversion Date Execution Date, curity or Exercise (Month/Day/Year) if any |         |         |            | ansaction of ode (Instr. Derivative                      |  | 6. Date Exercisable and<br>Expiration Date<br>(Month/Day/Year)                     |                  | 7. Title and<br>Amount of<br>Securities<br>Underlying<br>Derivative<br>Security (Inst<br>3 and 4) |                       |            | 8. Price of<br>Derivative<br>Security<br>(Instr. 5) | 9. Number<br>derivative<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported<br>Transaction<br>(Instr. 4) | y   | 10.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>I) (Instr. 4)   | 11. Nature<br>of Indirect<br>Beneficial<br>Ownership<br>(Instr. 4) |           |              |               |  |
|  |  |         |         |            | Code   |  | (A)  | (D)              | Date<br>Evercisable   |                       | Expiration | Title   | Amo<br>or<br>Num<br>of   | ber   |   |  |           |              |               |  |

## **Explanation of Responses:**

- 1. Represents shares automatically sold by the Reporting Person to satisfy withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 14, 2023. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement that includes a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 that was entered into on December 21, 2023, and the sale does not represent a discretionary trade by the Reporting Person.
- 2. The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$3.33 to \$3.35. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote
- 3. Includes 54,763 unvested restricted stock units.

/s/ Maiken Keson-Brookes, attorney-in-fact for Vicki L

11/08/2024

Goodman

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.